Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/340219
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | The rationale, design, and methods of a trial to evaluate the efficacy and safety of oxygen therapy in patients with intermediate-risk acute pulmonary embolism |
Autor: | Durán, Diego; Barrios, Deisy; Moisés, Jorge; Retegui, Ana; Rodríguez, Carmen CSIC ORCID ; Lobo, José Luis; López-Reyes, Raquel; Chasco-Eguilaz, Leyre; Jara Palomares, Luis CSIC ORCID; Monreal, Manuel; Bikdeli, Behnood; Jiménez, David CSIC ORCID | Fecha de publicación: | mar-2023 | Editor: | Elsevier | Citación: | American Heart Journal 257: 62-68 (2023) | Resumen: | [Background] In patients with intermediate-risk pulmonary embolism (PE), reversal of hypoxic vasoconstriction could constitute a target for treatment that protects the right ventricular (RV) function until endogenous fibrinolysis occurs. The Air vs oxygen for Intermediate-Risk pulmonary embolism (AIR) trial aims to assess the effect of oxygen therapy in patients with intermediate-risk acute PE who do not have hypoxemia at baseline. [Methods and analyses] AIR is a prospective, multicenter, randomized, open-label, parallel-group, proof-of-concept trial. A total of 90 patients hospitalized with intermediate-risk PE and an oxygen saturation of 90% or higher at baseline will be randomized in a 1:1 fashion to receive supplemental oxygen or ambient air. The primary outcome is a RV/LV diameter ratio equal or less than 1.0 on echocardiography measured 48 hours after the start of treatment. Secondary efficacy outcomes are the numerical change in the ratio of the RV to the LV diameter measured 48 hours and 7 days after the start of treatment, with respect to the baseline ratio measured at randomization. Clinical adverse events will be also collected. [Results] Enrollment started in July 2019 and is expected to proceed until 2022. Median age of the first 50 patients was 74 years (interquartile range, 61-81), and 50% were female. [Conclusions] This multicenter trial will provide information about the value of supplemental oxygen in patients with intermediate-risk acute PE who do not have hypoxemia at baseline. The results will contribute to research that may assist patients with intermediate-risk PE in the future. |
Versión del editor: | https://doi.org/10.1016/j.ahj.2022.11.017 | URI: | http://hdl.handle.net/10261/340219 | DOI: | 10.1016/j.ahj.2022.11.017 | ISSN: | 0002-8703 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Acceso_restringido.pdf | 108,79 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
2
checked on 21-abr-2024
Page view(s)
18
checked on 28-abr-2024
Download(s)
18
checked on 28-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.